Hostname: page-component-76d6cb85b7-8p85h Total loading time: 0 Render date: 2026-07-22T12:24:44.237Z Has data issue: false hasContentIssue false

RESPONSIVENESS OF THE EQ-5D TO CLINICAL CHANGE: IS THE PATIENT EXPERIENCE ADEQUATELY REPRESENTED?

Published online by Cambridge University Press:  05 February 2014

David Tordrup
Affiliation:
LSE Health, London School of Economics
Jean Mossman
Affiliation:
European Brain Council
Panos Kanavos
Affiliation:
Department of Social Policy and LSE Health, London School of Economics

Abstract

Objectives: In many economic evaluations and reimbursement decisions, quality-adjusted life-years (QALYs) are used as a measure of benefit to assess effectiveness of novel therapies, often based on the EQ-5D 3-level questionnaire. As only five dimensions of physical and mental well-being are reflected in this tool, significant aspects of the patient experience may be missed. We evaluate the use of the EQ-5D as a measurement of clinical change across a wide range of disorders from dermatological (acne) to life-threatening (metastatic cancers).

Methods: We analyze published studies on the psychometric properties of the EQ-5D 3-level questionnaire, extracting information on the Visual Analogue Scale versus Index score, Standardized Response Mean, and Effect Size. These are compared with ranges generally accepted to represent good responsiveness in the psychometric literature.

Results: We find that only approximately one in five study populations report subjective health state valuation of patients within 5 percent of the score attributed by the EQ-5D index, and more than 40 percent of studies report unacceptable ceiling effects. In the majority of studies, responsiveness of the EQ-5D index was found to be poor to moderate, based on Effect Size (63 percent poor–moderate) and Standardized Response Mean (72 percent poor–moderate).

Conclusions: We conclude that the EQ-5D index does not adequately reflect patient health status across a range of conditions, and it is likely that a significant proportion of the subjective patient experience is not accounted for by the index. This has implications for economic evaluations of novel drugs based on evidence generated with the EQ-5D.

Information

Type
Methods
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Supplementary material: File

Tordrup Supplementary Material

Tables and Figures

Download Tordrup Supplementary Material(File)
File 906.2 KB